MedDataX Logo

Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome

NCT ID: NCT00385099

Last Updated: 2017-08-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-08

Study Completion Date

2007-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see if GW876008 in Irritable Bowel Syndrome patients will reverse stress-induced hypersensitivity, by looking at thresholds for perception and pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679

NCT00511563

Irritable Bowel Syndrome
WITHDRAWN PHASE2

Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome

NCT00421707

Irritable Bowel Syndrome (IBS)
COMPLETED PHASE2

Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers

NCT00376896

Irritable Colon Irritable Bowel Syndrome (IBS)
COMPLETED PHASE1

A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)

NCT00394186

Irritable Bowel Syndrome (IBS)
COMPLETED PHASE2

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

NCT01340053

Constipation Predominant Irritable Bowel Syndrome
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Colon

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GW876008

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have irritable bowel syndrome.

Exclusion Criteria

* Subjects who have been taking any medication for the treatment of irritable bowel syndrome within 6 months prior to the start of the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRI103143

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide
NCT00584298 COMPLETED PHASE1
A Study of BMS-562086 in Patients With Irritable Bowel Syndrome
NCT00399438 COMPLETED PHASE2
Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome
NCT00135031 COMPLETED PHASE3
A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects
NCT02798991 COMPLETED PHASE1
Diarrhea Predominant Irritable Bowel Syndrome in Females
NCT00461526 COMPLETED PHASE2
A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers
NCT02727283 COMPLETED PHASE1
Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)
NCT00268879 COMPLETED PHASE3
Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)
NCT00101985 COMPLETED PHASE2
Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)
NCT01149200 COMPLETED PHASE2
A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome
NCT05780749 COMPLETED NA
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
NCT03154086 COMPLETED PHASE1
Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT00699166 COMPLETED PHASE2
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
NCT00394173 COMPLETED PHASE2
Genetic Carbohydrate Maldigestion as a Model to Study Food Hypersensitivity
NCT05795049 ACTIVE_NOT_RECRUITING
Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)
NCT00610909 COMPLETED PHASE4
Ethosuximide to Treat IBS
NCT02973542 UNKNOWN PHASE2
Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)
NCT00761007 COMPLETED PHASE2
Manipulation of Visceral Sensitivity and Immune System in IBS
NCT00418340 UNKNOWN PHASE4
Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome
NCT02079675 COMPLETED PHASE2
The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome
NCT02108119 COMPLETED PHASE2
Gastrointestinal Symptoms in Healthy Subjects and Patients With Irritable Bowel Syndrome
NCT01457378 COMPLETED
A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS.
NCT00139672 COMPLETED PHASE2
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT01844180 COMPLETED PHASE2
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
NCT03977155 COMPLETED PHASE2
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
NCT03573908 COMPLETED PHASE3